These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Genetic Analysis of Association Between Calcium Signaling and Hippocampal Activation, Memory Performance in the Young and Old, and Risk for Sporadic Alzheimer Disease. Heck A; Fastenrath M; Coynel D; Auschra B; Bickel H; Freytag V; Gschwind L; Hartmann F; Jessen F; Kaduszkiewicz H; Maier W; Milnik A; Pentzek M; Riedel-Heller SG; Spalek K; Vogler C; Wagner M; Weyerer S; Wolfsgruber S; de Quervain DJ; Papassotiropoulos A JAMA Psychiatry; 2015 Oct; 72(10):1029-36. PubMed ID: 26332608 [TBL] [Abstract][Full Text] [Related]
44. Episodic memory decline in Parkinson' s disease: relation with white matter hyperintense lesions and influence of quantification method. Dunet V; Fartaria MJ; Deverdun J; Le Bars E; Maury F; Castelnovo G; Kober T; Cuadra MB; Geny C; Marechal B; de Champfleur NM Brain Imaging Behav; 2019 Jun; 13(3):810-818. PubMed ID: 29948903 [TBL] [Abstract][Full Text] [Related]
45. Dopamine and Consolidation of Episodic Memory: Timing is Everything. Grogan J; Bogacz R; Tsivos D; Whone A; Coulthard E J Cogn Neurosci; 2015 Oct; 27(10):2035-50. PubMed ID: 26102227 [TBL] [Abstract][Full Text] [Related]
46. Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson's disease. Prediger RD; Rojas-Mayorquin AE; Aguiar AS; Chevarin C; Mongeau R; Hamon M; Lanfumey L; Del Bel E; Muramatsu H; Courty J; Raisman-Vozari R J Neural Transm (Vienna); 2011 Aug; 118(8):1215-25. PubMed ID: 21301897 [TBL] [Abstract][Full Text] [Related]
47. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Cooper JA; Sagar HJ; Jordan N; Harvey NS; Sullivan EV Brain; 1991 Oct; 114 ( Pt 5)():2095-122. PubMed ID: 1933236 [TBL] [Abstract][Full Text] [Related]
48. Insights into the structure and function of the hippocampal formation: Relevance to Parkinson's disease. Györfi O; Nagy H; Bokor M; Kéri S Ideggyogy Sz; 2018 Jan; 71(1-02):15-24. PubMed ID: 29465896 [TBL] [Abstract][Full Text] [Related]
49. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? Jellinger KA J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901 [TBL] [Abstract][Full Text] [Related]
56. Hippocampal formation alterations differently contribute to autobiographic memory deficits in mild cognitive impairment and Alzheimer's disease. Hirjak D; Wolf RC; Remmele B; Seidl U; Thomann AK; Kubera KM; Schröder J; Maier-Hein KH; Thomann PA Hippocampus; 2017 Jun; 27(6):702-715. PubMed ID: 28281317 [TBL] [Abstract][Full Text] [Related]
57. Current management of the cognitive dysfunction in Parkinson's disease: how far have we come? Vale S Exp Biol Med (Maywood); 2008 Aug; 233(8):941-51. PubMed ID: 18535172 [TBL] [Abstract][Full Text] [Related]
58. Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease. Masilamoni GJ; Smith Y J Neural Transm (Vienna); 2018 Mar; 125(3):337-363. PubMed ID: 28861737 [TBL] [Abstract][Full Text] [Related]
59. Source memory in normal aging and Parkinson's disease. Davidson PS; Cook SP; McGhan L; Bouchard T; Camicioli R J Neuropsychol; 2013 Sep; 7(2):179-92. PubMed ID: 23560529 [TBL] [Abstract][Full Text] [Related]
60. Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. Lewis SJ; Cools R; Robbins TW; Dove A; Barker RA; Owen AM Neuropsychologia; 2003; 41(6):645-54. PubMed ID: 12591022 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]